博瑞医药：关于收到上海证券交易所《关于终止对博瑞生物医药（苏州）股份有限公司向特定对象发行股票审核的决定》的公告

Core Viewpoint - 博瑞医药 has decided to terminate its plan for a specific issuance of A-shares for the year 2024 and has withdrawn the application documents [2] Group 1 - 博瑞医药 will hold its fourth board meeting on October 15, 2025, to review the decision to terminate the issuance of A-shares [2] - The related director, 袁建栋, abstained from voting on this matter [2] - On October 17, 2025, 博瑞医药 received a decision from the Shanghai Stock Exchange to terminate the review of its application for the issuance of shares [2]